Skip to content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Risk of seizures after immunization in children with epilepsy: a risk interval analysis

BMC PediatricsBMC series – open, inclusive and trusted201818:134

https://doi.org/10.1186/s12887-018-1112-0

Received: 29 August 2017

Accepted: 4 April 2018

Published: 11 April 2018

Abstract

Background

In children with epilepsy, fever and infection can trigger seizures. Immunization can also induce inflammation and fever, which could theoretically trigger a seizure. The risk of seizure after immunization in children with pre-existing epilepsy is not known. The study objective was to determine the risk of medically attended seizure after immunization in children with epilepsy < 7 years of age.

Methods

We conducted a retrospective study of children < 7 years of age with epilepsy in Nova Scotia, Canada from 2010 to 2014. Hospitalizations, emergency visits, unscheduled clinic visits, and telephone calls for seizures were extracted from medical records. Immunization records were obtained from family physicians and Public Health with informed consent. We conducted a risk interval analysis to estimate the relative risk (RR) of seizure during risk periods 0–14, 0–2, and 5–14 days post-immunization versus a control period 21–83 days post-immunization.

Results

There were 302 children with epilepsy who were eligible for the study. Immunization records were retrieved on 147 patients (49%), of whom 80 (54%) had one or more immunizations between the epilepsy diagnosis date and age 7 years. These 80 children had 161 immunization visits and 197 medically attended seizures. Children with immunizations had more seizures than either those with no immunizations or those with no records (mean 2.5 versus 0.7 versus 0.9, p < 0.001). The risk of medically attended seizure was not increased 0–14 days after any vaccine (RR = 1.1, 95% confidence interval (CI): 0.5–2.8) or 0–2 days after inactivated vaccines (RR = 0.9, 95% CI: 0.1–7.1) versus 21–83 days post-immunization. No seizure events occurred 5–14 days after live vaccines.

Conclusions

Children with epilepsy do not appear to be at increased risk of medically attended seizure following immunization. These findings suggest that immunization is safe in children with epilepsy, with benefits outweighing risks.

Keywords

Adverse event following immunizationEpilepsySeizureVaccinationVaccine safety

Background

Immunization programs are among the most effective public health interventions ever developed. [1] However, as the incidence of vaccine-preventable infections has decreased, healthcare professionals and the public have become increasingly concerned about the risk of adverse events following immunization (AEFIs). [2] Neurological events are among the most serious AEFIs, frequently resulting in emergency visits or hospitalization. Seizure is both the most frequent neurological AEFI reported and the most common neurological disorder in children. [3] Up to 10% of children will experience a seizure by their 16th birthday, and approximately 0.5% of children have epilepsy, making it one of the more common chronic diseases in children. [46]

Certain vaccines [e.g., measles-mumps-rubella (MMR) vaccine, trivalent inactivated influenza vaccine] have been associated with febrile seizures in young children. [711] The timing of febrile seizures after immunization coincides with the peak inflammatory response. Inactivated vaccines such as inactivated influenza vaccine stimulate an immune response within hours, inducing fever (and febrile seizure) within 1–2 days after immunization. [7, 8] After live vaccines (e.g., MMR), the risk of febrile seizure is delayed until 5–14 days post-immunization, after the attenuated virus has reached sufficient levels in the bloodstream to be detected by the immune system. [9, 10] In contrast, immunizations have not been associated with afebrile seizures in large cohort studies, and several studies and reviews concluded that immunizations do not trigger the onset of epilepsy [9, 1215]. However, the risk of seizure after routine immunizations in children with pre-existing epilepsy has not been systematically evaluated. Despite limited direct evidence of vaccine safety in this population, current practice guidelines recommend that children with epilepsy follow the routine immunization schedule. [16]

The study objective was to estimate the relative risk of medically attended seizure after immunization among children less than 7 years of age with a diagnosis of epilepsy. Evidence of the safety of immunization in these children would reassure parents and healthcare providers concerned about the risk of immunization-induced seizures.

Methods

Study design and subjects

We conducted a retrospective cohort study of children diagnosed with epilepsy before 7 years of age who lived in Nova Scotia, Canada and were followed by the IWK Health Centre Neurology Service between January 2010 and December 2014. The IWK Health Centre is the only pediatric tertiary care center in the province of Nova Scotia (2016 population: 949,500 [17]) and the IWK Neurology Service follows approximately 95% of children with epilepsy in the province. [18] Children were eligible for the study if they had a neurologist diagnosis of epilepsy before their seventh birthday, were seen by a neurologist based at the IWK between 2010 and 2014, and were a resident of Nova Scotia on the date of the first clinic visit. Children with a history of seizures that occurred exclusively during the neonatal period or only with fever (i.e., febrile seizures) were excluded.

Children with epilepsy were identified by screening medical records of patients seen in the IWK Neurology Clinic. Caregivers of children who met the inclusion criteria were contacted initially via mail, followed by a telephone call inviting them to participate in the study by providing their verbal and/or written consent to release their child’s immunization records. The study team attempted to contact caregivers by telephone up to five times, calling at different times of the day and leaving up to two messages.

Data sources

Healthcare encounters for new or escalating seizures, including hospitalizations, emergency visits, unscheduled outpatient visits and telephone calls to the neurologist were extracted from the electronic medical record and Neurology clinic chart. Families of children with epilepsy are instructed to call the on-call neurologist to notify them of seizure events and request advice; details of these calls are recorded in the clinic chart. Patient demographics (sex, month/year of birth), age at epilepsy diagnosis, epilepsy type [severe epilepsy (defined as severe myoclonic epilepsy of infancy/Dravet syndrome, infantile spasms, and Lennox Gastaux syndrome), partial (focal) epilepsy, idiopathic generalized epilepsy (including absence epilepsy), unclassified epilepsy], antiepileptic therapy, and dates of healthcare encounters were collected.

Immunization records were retrieved from the child’s family physician and/or Nova Scotia Public Health Services. In Nova Scotia, at least 80% of immunizations among children < 7 years of age are administered by family physicians who are required to submit a notification form to Public Health with the details of the vaccines administered. Approximately 20% of immunizations are administered by public health nurses. To ensure data completeness, immunization dates and vaccines administered were extracted from both sources whenever possible.

Statistical analysis

The primary exposure was any immunization received between the date of epilepsy diagnosis and the seventh birthday. The primary outcome was seizure requiring medical attention between the date of epilepsy diagnosis and the seventh birthday. For patients with > 1 healthcare encounter within 24 h, the highest acuity healthcare encounter was included in the analysis. Age at diagnosis, epilepsy type, and number of seizure events were compared among children with and without immunization visits and those whose records were not available (includes children who did not consent and those who consented but whose records were not available from either Public Health or the primary care physician). Categorical variables were assessed by χ2 test or Fisher’s exact tests for expected cell sizes < 5 and continuous variables were assessed by ANOVA. Statistical significance was defined as p < 0.05.

The risk of seizure-related healthcare encounter after immunization was assessed in a risk interval analysis using unconditional Poisson regression models. [19] This approach compares the rate of adverse events during a “risk period” when an adverse reaction to the vaccine is biologically plausible, to the rate during a “control period” remote from immunization when the vaccine cannot be implicated. Assuming causality, the relative risk (RR) of seizure during the risk versus control windows corresponds to the RR of vaccine-attributable events. This approach implicitly adjusts for fixed confounders (e.g., epilepsy type). The RR of seizure requiring medical attention was assessed during five risk periods: 0–14 days after any vaccine, 0–2 days after inactivated vaccine, 0–3 days after inactivated vaccine, 7–10 days after live vaccine, and 5–14 days after a live vaccine. A control period of 21–83 days post-immunization was used for all analyses. A control period of 7–83 days pre-immunization was used in a sensitivity analysis. Days 15–20 represented the “washout period”. A seizure event occurring during the same risk or control window was counted as a separate event if it occurred > 24 h after the first. Age and calendar season were assessed as potential confounders in the Poisson regression models. Statistical analysis was conducted using SAS version 9.4 (SAS Institute, Cary, NC).

Results

In total, 302 children met the inclusion criteria, of whom 38% had partial (focal) epilepsy, 33% had unclassified epilepsy, 18% had idiopathic generalized epilepsy (52% of whom had absence epilepsy), 5% had benign childhood epilepsy with centrotemporal spikes (benign rolandic epilepsy), and 4% had severe epilepsy. Parents of 166 children consented to release their immunization records (Fig. 1). Immunization information was available on 147 children from either Public Health or the primary care physician. Eighty children had one or more immunization visits between their epilepsy diagnosis and 7th birthday. Demographic and clinical characteristics are shown in Table 1. Children with immunization events were diagnosed at a younger mean age (2.1 years versus 4.0 years versus 3.1 years, p < 0.001) and had more seizure events during the observation period (mean events per subject = 2.5 versus 0.7 versus 0.9, p < 0.001) than either children with no immunization events or children whose records were unavailable.
Fig. 1

Summary of eligible subjects who did and did not provide consent to release their immunization records. Eligible immunization visits include immunizations administered between the date of the epilepsy diagnosis and the seventh birthday

Table 1

Characteristics of children under 7 years of age with epilepsy seen between 2010 and 2014 (N = 302)

Characteristics

Patients with immunization visits (N = 80)

Patients with no immunization visits (N = 67)

Patients with no immunization records (N = 155)

P

 

n (%)

n (%)

n (%)

 

Sex

 Male

37 (46)

33 (49)

76 (49)

0. 93

 Female

43 (54)

34 (51)

79 (51)

 

Age at epilepsy diagnosis

 mean (SD), in years

2.1 (1.6)

4.0 (2.1)

3.1 (2.1)

< 0.001

Place of residence

 Halifax Regional Municipality

29 (36)

22 (33)

63 (41)

0.34

 Outside Halifax

51 (64)

45 (67)

92 (59)

 

Epilepsy type

0.06

 Severe epilepsy

7 (9)

5 (7)

3 (2)

 

 Partial epilepsy

33 (41)

19 (28)

62 (40)

 

 Unclassified epilepsy

26 (32)

21 (31)

52 (34)

 

 Other types

14 (18)

22 (33)

38 (25)

 

Number of seizure events

mean (SD)

2.5 (3.2)

0.7 (1.5)

0.9 (1.6)

< 0.001

Antiepileptic medications

0.01

 0

6 (7)

9 (13)

36 (23)

 

 1

55 (69)

45 (67)

99 (64)

 

  ≥ 2

19 (24)

13 (19)

2 (13)

 

CI, confidence interval; SD, standard deviation

There were 161 immunization events among the 80 subjects who received immunizations between their epilepsy diagnosis and seventh birthday (Table 2). Thirty-nine of 59 (67%) children with immunization records who were diagnosed with epilepsy before 4 years of age and followed until ≥6 years of age had ≥1 immunization visit. Inactivated vaccines were administered at nearly all immunization visits, either alone or with live vaccines.
Table 2

Immunizations administered after epilepsy diagnosis

 

N

%

Number of immunization visits per subject (N = 80)

 1

45

31

  ≥ 2

35

24

Vaccine type(s) administered at immunization visits (N = 161)

 Inactivated vaccine(s) only

94

58

 Live vaccine(s) only

7

4

 Live and inactivated vaccines co-administered

60

37

 DTaP

76

47

 Influenza

27

17

 MenC

7

4

 MMR/MMRV

22

14

 PCV

16

10

 Rotavirus

3

2

 Varicella

5

3

 Other

5

3

Age at immunization event (N = 161)

 0–11 months

39

24

 12–23 months

47

29

 24–47 months

21

13

 48–83 months

54

34

Season of immunization (N = 161)

 Winter

30

19

 Spring

30

19

 Summer

56

35

 Fall

45

28

DTaP, Diphtheria-Tetanus-acellular Pertussis; MenC, meningococcal conjugate vaccine; MMR, measles-mumps-rubella; MMRV, measles-mumps-rubella-varicella; PCV, pneumococcal conjugate vaccine

Children with immunization visits had a total of 197 healthcare encounters for seizure during the study period. The majority of encounters were telephone calls to the neurologist (131/197; 66%), followed by ED visits (31/197; 16%), hospitalizations (20/197; 10%), and unscheduled outpatient visits (15/197; 8%). The number of seizure events was similar across all four seasons, ranging from 54 events in winter (27%) to 43 events in summer (22%). The mean age at the time of the seizure event was 3.5 years (standard deviation = 1.7).

The results of the risk interval analysis are shown in Table 3. The relative risk of seizure was not increased during the risk period 0–14 days after any vaccine versus the control period 21–83 days post-immunization (RR = 1.14, 95% CI: 0.46, 2.83). Similarly, there was no increase in the relative risk of seizure events 0–2 days versus 21–83 days after inactivated vaccines. No seizure events occurred during the risk periods 7–10 days or 5–14 days after a live vaccine; therefore the RR could not be estimated. In sensitivity analyses, the RR was estimated using a 0–3 day risk interval after inactivated vaccines, and a control period of 7–83 days prior to immunization (see Additional file 1). In all models, the estimate of RR was similar to the primary analysis.
Table 3

Risk interval analysis among children with epilepsy and immunization events (N = 80)

Vaccine type

Healthcare encounters for seizure after immunization

RRa

 

Risk period

Control period

 

0–14 days

0–2 days

7–10 days

5–14 days

21–83 days

(95% CI)

Any type

6

20

1.14 (0.46, 2.83)

Inactivated

1

20

0.95 (0.13, 7.06)

Live

0

0

10

-b

RR, relative risk

aIncluding age or calendar season in the model did not change the estimate of RR, therefore the unadjusted models are presented

b Unable to estimate RR

The rate of seizure events during the 0–14 day risk period after any immunization was 0.92 events per person-year versus 0.76 events per person-year during the control period, which corresponds to a rate difference of 0.16 seizure events per person-year (95% CI: -0.67, 0.98). The upper confidence limit corresponds to 1 additional seizure event in the 0–14 day risk period per 25 immunizations. The rate of seizure events was 0.790 per person-year during the 0–2 day risk period versus 0.788 per person-year in the control period, corresponding to a rate difference of 0.002 seizures per person-year (95% CI: -1.611, 1.615). The upper confidence limit corresponds to 1 additional seizure event in the 0–2 day risk period per 75 inactivated immunizations.

Discussion

In this study, children < 7 years of age who were followed by a neurologist for epilepsy did not appear to be at increased risk of seizure requiring medical attention after any immunization or after inactivated vaccines, compared to their baseline risk. The lack of seizure events during the risk periods after live vaccines suggests that the risk of seizure is not increased after live vaccines, although the relative risk could not be estimated.

The study findings are consistent with a self-controlled case series of adults and children 0–24 years of age with and without epilepsy which found no increased risk of seizure requiring inpatient or outpatient hospital care during the risk periods 0–7 days or 8–30 days after adjuvanted pandemic H1N1 influenza immunization versus the controls periods 31–90 days pre-immunization or 31–90 days post-immunization. [20] However, the risk was not assessed specifically in young children and the 0–7 day risk period may have been too long to detect a transient increase in risk 24–48 h after an inactivated vaccine. [7, 8] In addition, this study captured only seizure events severe enough to require hospital care, while our study also captured non-severe seizure events managed via telephone or in the outpatient clinic.

In contrast, a study of 17 children with severe myoclonic epilepsy of infancy whose parents completed seizure diaries after MMR immunization reported an incidence rate ratio of parent-reported seizure of 2.3 (95% CI: 1.5–3.4) in the 5–12 days after the first MMR dose versus the control periods of 0–4 days and 13–42 days post-immunization. [21] Children with severe myoclonic epilepsy of infancy are particularly susceptible to fever-induced seizure, which may explain the increased risk of seizures after MMR vaccine during the period when MMR-associated febrile seizures are observed. In addition, in 16% to 21% of children with severe myoclonic epilepsy of infancy, their first seizure occurred after immunization. [21, 22] Only 15 children in our study had a severe epilepsy syndrome (severe myoclonic epilepsy of infancy, infantile spasms, or Lennox-Gastaux syndrome); therefore, we are unable to exclude a risk in this subgroup. While we may have expected to see an increased risk of seizures after MMR/MMRV in this study, most participants were diagnosed with epilepsy after 12 months of age when the first dose is recommended. The second MMR dose does not appear to be associated with an increased risk of febrile seizure. [23] Further evaluation of vaccine safety in these high-risk children is needed.

Although not an objective of our study, our results provide some evidence to suggest that children with epilepsy may be underimmunized for their age. Only 17% of children with immunization records had received influenza vaccine which is recommended annually for all children over 6 months of age, especially those with epilepsy who are at increased risk of severe influenza. [24] Twenty of 147 (14%) children whose immunization records were available had no recorded immunization events between ages 4 and 7 years, suggesting that they had not received their preschool booster immunizations. It is not clear whether these children were less likely to be immunized than children without epilepsy as overall vaccine coverage in Nova Scotia is below target levels. [25] However, limited evidence suggests that children with epilepsy are less likely to be fully immunized than children without epilepsy. [26, 27] Whether a diagnosis of epilepsy negatively impacts future vaccine uptake is an important question that merits further study.

This study had limitations. We were unable to obtain immunization records on all patients and records may have been incomplete, underlining the importance of central immunization registries for evaluating vaccine safety. Children with immunization events experienced more seizure events than those without immunization events or whose records were not available, which would be expected to lead to an overestimation of the risk of post-immunization seizure. Ascertainment of healthcare encounters for seizure may have been incomplete if some telephone calls to the neurologist were not documented or if some emergency visits and admissions to hospitals outside of the IWK were not reported to the neurologist. In addition, if parents were warned that seizures could occur after immunization, they may have been less likely to report post-immunization seizures. This could have led to an underestimation of the risk of post-immunization seizure. The precision of the results was limited by the small sample size and there were no healthcare encounters during the risk period after a live vaccine, which precluded determination of the relative risk. Nonetheless, we demonstrated that the upper limit of the attributable risk of seizure during the 0–14 day and 0–2 day risk intervals was only 1 seizure per 25 immunizations and 1 per 75 inactivated immunizations, respectively, with two-thirds of events being mild enough to be managed by telephone. A strength of this study was the ascertainment of both severe and non-severe seizure events after immunization among children with all types of epilepsy.

Conclusions

Parents and vaccine providers can be reassured that children with epilepsy do not appear to be at increased risk of medically attended seizure after immunization. While a small increased risk of seizure after immunization cannot be excluded, when balanced against the risk of seizure associated with a vaccine-preventable infection, the benefits appear to outweigh the risks. Further studies are needed in different populations to confirm these findings.

Abbreviations

AEFI: 

Adverse event following immunization

CI: 

Confidence interval

ED: 

Emergency department

MMR: 

Measles-mumps-rubella vaccine

RR: 

Relative risk

Declarations

Acknowledgements

The authors would like to acknowledge the staff at the Canadian Center for Vaccinology for their assistance with recruitment, data collection, data management and statistical analysis, particularly Donna MacKinnon-Cameron.

Funding

This study was funded by a grant from the IWK Health Center. KAT received salary support through an IWK Investigatorship.

Availability of data and materials

Datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

KAT conceived of the study idea, developed the protocol, oversaw data collection, interpreted the results, and wrote the manuscript. PB contributed to the protocol development, data collection, interpretation of the results and reviewed and approved the manuscript. LY contributed to developing the analysis plan, conducted the analysis and reviewed and approved the manuscript. BS contributed to protocol development, analysis, interpretation of results and reviewed and approved the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study received ethics approval from the IWK Research Ethics Board (Project #1016041). Caregivers of participants were required to provide verbal and/or written consent.

Competing interests

KAT has received research support and consultancy fees from Pfizer and a grant from GlaxoSmithKline outside the submitted work. The other authors have no disclosures.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Pediatrics, Dalhousie University, Halifax, Canada
(2)
Department of Community Health & Epidemiology, Dalhousie University, Halifax, Canada
(3)
Canadian Center for Vaccinology, IWK Health Centre, Halifax, Canada
(4)
Department of Mathematics and Statistics, Dalhousie University, Halifax, Canada

References

  1. Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, Lee BW, Lolekha S, Peltola H, Ruff TA, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86:140–6.View ArticlePubMedGoogle Scholar
  2. Callreus T. Perceptions of vaccine safety in a global context. Acta Paediatr. 2010;99:166–71.PubMedGoogle Scholar
  3. Friedman MJ, Sharieff GQ. Seizures in children. Pediatr Clin N Am. 2006;53:257–77.View ArticleGoogle Scholar
  4. Wiebe S, Bellhouse DR, Fallahay C, Eliasziw M. Burden of epilepsy: the Ontario health survey. Can J Neurol Sci. 1999;26:263–70.View ArticlePubMedGoogle Scholar
  5. Kozyrskyj AL, Prasad AN. The burden of seizures in Manitoba children: a population-based study. Can J Neurol Sci. 2004;31:48–52.View ArticlePubMedGoogle Scholar
  6. Prasad AN, Sang X, Corbett BA, Burneo JG. Prevalence of childhood epilepsy in Canada. Can J Neurol Sci. 2011;38:719–22.View ArticlePubMedGoogle Scholar
  7. Armstrong PK, Dowse GK, Effler PV, Carcione D, Blyth CC, Richmond PC, Geelhoed GC, Mascaro F, Scully M, Weeramanthri TS. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open. 2011;1:e000016.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM, Group VSDRCAIW. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink project, 2010-2011. Vaccine. 2012;30:2024–31.Google Scholar
  9. Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Ward JI, Marcy SM, et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. N Engl J Med. 2001;345:656–61.View ArticlePubMedGoogle Scholar
  10. MacDonald SE, Dover DC, Simmonds KA, Svenson LW. Risk of febrile seizures after first dose of measles-mumps-rubella-varicella vaccine: a population-based cohort study. CMAJ. 2014;186:824–9.View ArticlePubMedPubMed CentralGoogle Scholar
  11. IOM (Institute of Medicine). Measles, mumps, and rubella vaccine. In: Stratton K, Ford A, Rusch E, Wright Clayton E, editors. Adverse effects of vaccines: evidence and causality. Washington, DC: The National Academies Press; 2012.Google Scholar
  12. Huang WT, Gargiullo PM, Broder KR, Weintraub ES, Iskander JK, Klein NP, Baggs JM, Vaccine Safety Datalink Team. Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics. 2010;126:263–9.Google Scholar
  13. Verbeek NE, Jansen FE, Vermeer-de Bondt PE, de Kovel CG, van Kempen MJ, Lindhout D, Knoers NV, van der Maas NA, Brilstra EH. Etiologies for seizures around the time of vaccination. Pediatrics. 2014;134:658–66.View ArticlePubMedGoogle Scholar
  14. Ward KN, Bryant NJ, Andrews NJ, Bowley JS, Ohrling A, Verity CM, Ross EM, Miller E. Risk of serious neurologic disease after immunization of young children in Britain and Ireland. Pediatrics. 2007;120:314–21.View ArticlePubMedGoogle Scholar
  15. IOM (Institute of Medicine): The childhood immunization schedule and safety: Stakeholder concerns, scientific evidence, and future studies. In. Washington, DC: The National Academies Press; 2013.Google Scholar
  16. Pruna D, Balestri P, Zamponi N, Grosso S, Gobbi G, Romeo A, Franzoni E, Osti M, Capovilla G, Longhi R, et al. Epilepsy and vaccinations: Italian guidelines. Epilepsia. 2013;54(Suppl 7):13–22.View ArticlePubMedGoogle Scholar
  17. Population by year, by province and territory. [http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo02a-eng.htm]. Accessed 9 Apr 2018.
  18. Camfield CS, Camfield PR, Gordon K, Wirrell E, Dooley JM. Incidence of epilepsy in childhood and adolescence: a population-based study in Nova Scotia from 1977 to 1985. Epilepsia. 1996;37:19–23.View ArticlePubMedGoogle Scholar
  19. Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, Kleinman K, Mullooly JP, France EK. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol. 2006;59:808–18.View ArticlePubMedGoogle Scholar
  20. Arnheim-Dahlstrom L, Hallgren J, Weibull CE, Sparen P. Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study. BMJ. 2012;345:e7594.Google Scholar
  21. Verbeek NE, van der Maas NA, Sonsma AC, Ippel E, Vermeer-de Bondt PE, Hagebeuk E, Jansen FE, Geesink HH, Braun KP, de Louw A, et al. Effect of vaccinations on seizure risk and disease course in Dravet syndrome. Neurology. 2015;85:596–603.View ArticlePubMedGoogle Scholar
  22. Tro-Baumann B, von Spiczak S, Lotte J, Bast T, Haberlandt E, Sassen R, Freund A, Leiz S, Stephani U, Boor R, et al. A retrospective study of the relation between vaccination and occurrence of seizures in Dravet syndrome. Epilepsia. 2011;52:175–8.View ArticlePubMedGoogle Scholar
  23. Klein NP, Lewis E, Baxter R, Weintraub E, Glanz J, Naleway A, Jackson LA, Nordin J, Lieu T, Belongia EA, et al. Measles-containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012;129:809–14.View ArticlePubMedGoogle Scholar
  24. National Advisory Committee on Immunization. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2016–2017. In: Canadian Immunization Guide. Ottawa: Public Health Agency of Canada; 2016. p. 1–60.Google Scholar
  25. Public Health Agency of Canada. Vaccine coverage in Canadian children: Results from the 2013 childhood National Immunization Coverage Survey (cNICS). Ottawa: Public Health Agency of Canada; 2016.Google Scholar
  26. Pandolfi E, Carloni E, Marino MG, Ciofi degli Atti ML, Gesualdo F, Romano M, Giannattasio A, Guarino A, Carloni R, Borgia P, et al. Immunization coverage and timeliness of vaccination in Italian children with chronic diseases. Vaccine. 2012;30:5172–8.View ArticlePubMedGoogle Scholar
  27. Tillmann BU, Tillmann HC, Heininger U, Lutschg J, Weber P. Acceptance and timeliness of standard vaccination in children with chronic neurological deficits in North-Western Switzerland. Eur J Pediatr. 2005;164:320–5.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement